January 11, 2017
Evgen Pharma gets positive DSMB review of SAS trial
Evgen Pharma’s anti-stress drug SFX-01, which is currently in its Phase II study has shown good results and it can proceed as planned.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
January 11, 2017
FDA calls for more patient enrollments
The U.S. Food and Drug Administration (FDA) has noticed that lately for certain reason, there are fewer number of people willing to participate in clinical trials for different medications. Therefore, it has decided to encourage patients to take a part in helping researching companies to develop new drugs.
January 10, 2017
Japanese Takeda in a $5.2 billion acquisition deal with USA-based Ariad
Takeda has ensured the signature to buy USA-based drugmaker focused on producing cancer treatments, Ariad Pharmaceuticals for about $5.2 billion, or $24 per share in cash for stockholders.
January 10, 2017
Regeneron CEO says Amgen not putting patients first in patent dispute
Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.
January 10, 2017
Spineway finds new distributor in Texas, U.S.
Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), has signed an distribution agreement…
January 10, 2017
Cumberland Pharmaceuticals to distribute Clinigen’s cancer treatment aid Totect in U.S.
Clinigen Group has made a deal with Cumberland Pharmaceuticals to market another product in the US, this time an oncology drug Totect (dexrazoxane hydrochloride).
January 9, 2017
Allergan expands its neurological diseases arm, buys Lysosomal Therapeutics
Allergan has purchased an exclusive option right to acquire Lysosomal Therapeutics (LTI), the company focused on innovative small-molecule research and…
January 9, 2017
Roche gets FDA’s priority review for Tecentriq to treat different type of bladder cancer
Roche said on Monday that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) for metastatic urothelial carcinoma (mUC).
January 9, 2017
Celyad’s patent holds up after being challenged by third party
U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary…
January 6, 2017
BMS tries out GeneCentric’s Cancer Subtype Platform for Opdivo clinical trials
Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.